Clinical trials
Relapsed or Refractory Peripheral T Cell Lymphoma clinical trials
Below are recruiting relapsed or refractory peripheral t cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,702 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05091424RecruitingPhase 1
Mosunetuzumab with or without venetoclax for CLL
This Phase 1 study tests whether mosunetuzumab alone or with venetoclax is safe and effective for people with chronic lymphocytic leukemia (CLL) that came back or did not respond to prior treatment. It may help by controlling the CLL immune system response while also studying dosing and side effects.
Rochester, MinnesotaAges 18 years+ - NCT04879043RecruitingPhase 1/Phase 2
Safety study of HDP-101 for relapsed myeloma patients
This early-phase trial tests whether HDP-101 is safe and can potentially help adults with multiple myeloma that has come back or didn’t respond to standard treatments. It focuses on people who have already tried key myeloma medicines and still have measurable disease.
Atlanta, GeorgiaAges 18 years+ - NCT04421560RecruitingPhase 1/Phase 2
Testing pembrolizumab, ibrutinib, and rituximab for PCNSL
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
Boston, MassachusettsAges 18 years+ - NCT07735533RecruitingPhase 1/Phase 2
UB-VV400 with rapamycin for large B-cell lymphoma
This trial tests an experimental treatment called UB-VV400 given with another drug, rapamycin, for people with large B-cell lymphoma that has not responded to standard therapy. The treatment targets a protein called CD22 on lymphoma cells and may help your immune system fight the cancer.
Nashville, TennesseeAges 18 years+ - NCT06340737RecruitingPhase 1
CD22-targeting CAR T cells for relapsed B cell lymphoma
This trial tests whether giving modified immune cells (CAR T cells) that target CD22 on cancer cells can help people with certain B-cell lymphomas that have come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors or control the disease.
Palo Alto, CaliforniaAges 18 years+ - NCT06045910RecruitingPhase 1/Phase 2
A study of ALETA-001 for certain B-cell blood cancers
This trial tests a new treatment called ALETA-001 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments, including CAR T-cell therapy. It aims to see if ALETA-001 can help when standard options have not worked.
BirminghamAges 16 years+ - NCT05365659RecruitingPhase 1
Testing IKS03 for advanced B-cell lymphoma
This trial tests a new study drug, IKS03, for people with advanced B-cell non-Hodgkin lymphoma that has not responded to at least two prior treatments. The goal is to see if the drug is safe and how well it works.
Baltimore, MarylandAges 18 years+ - NCT06015880RecruitingPhase 1
Combination drug therapy for relapsed or resistant large B-cell lymphoma
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT05544968RecruitingPhase 1
CD30-targeted cell treatment for hard-to-treat blood cancers
This Phase 1 trial studies an experimental treatment that targets a marker called CD30 on cancer cells. It is for adults with certain relapsed or refractory CD30-positive blood cancers to see how well the treatment works and what side effects it causes.
Milwaukee, WisconsinAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT06081478RecruitingPhase 2
Targeted CAR-T cell therapy for advanced lymphoma or leukemia
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
Beijing, Beijing MunicipalityAges 14–85 - NCT05887167RecruitingPhase 1
Test safety of making CAR T cells from your own blood
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
Los Angeles, CaliforniaAges 18–85 - NCT07502118RecruitingPhase 2/Phase 3
NexCAR19 for B-cell blood cancers that came back
This trial tests NexCAR19 (a CAR-T cell therapy) for people with certain types of B-cell lymphoma or B-cell acute lymphoblastic leukemia that didn't respond to or came back after other treatments. It aims to see if this therapy can help control the cancer.
AnkaraAges 18 years+ - NCT06464861RecruitingPhase 1
Sequential CD19 CAR-NK and CAR-T for B-cell lymphoma
This trial tests a new combination treatment: first, natural killer cells (NK cells) that are engineered to find CD19, followed by CAR-T cells (also targeting CD19). It is for people with B-cell lymphoma that has come back or not responded to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06564038RecruitingPhase 1/Phase 2
Study of AZD0486 alone or with other drugs for B-cell cancers
This trial tests a new drug called AZD0486, alone or with other medicines, for people with certain types of B-cell cancers that have come back or not responded to treatment. The goal is to see how safe and effective it is.
Boston, MassachusettsAges 18 years+ - NCT05098613RecruitingPhase 1
Testing a new immune cell therapy for relapsed B-cell lymphoma
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
Aurora, ColoradoAges 16 years+ - NCT04797767RecruitingPhase 1/Phase 2
Venetoclax plus CLAG-M for high-risk AML
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
Seattle, WashingtonAges 18 years+ - NCT06925464RecruitingPhase 1/Phase 2
Modified immune cells for T-cell lymphoma
This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 14–70 - NCT07022964RecruitingPhase 1/Phase 2
CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
BeijingAges 14–70 - NCT07451054RecruitingPhase 1
Stem cells plus CAR T-cells for lymphoma
This trial tests a new treatment that combines your own stem cells with special immune cells (CAR T-cells) that target a marker called CD45 on lymphoma cells. It may help people whose lymphoma has not responded to multiple prior therapies.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07197307RecruitingPhase 2
Study of two targeted drugs for relapsed aggressive B-cell lymphoma
This study tests a new combination of two drugs—loncastuximab tesirine (an antibody-drug conjugate) and epcoritamab (a bispecific antibody)—for people whose aggressive B-cell lymphoma has returned or not responded to prior treatment. The goal is to see if the combination is safe and effective.
AachenAges 18 years+ - NCT05010005RecruitingPhase 1
Testing ruxolitinib plus duvelisib for relapsed T-cell lymphoma
This Phase 1 study tests how safe and effective ruxolitinib plus duvelisib are in adults with certain types of mature T-cell lymphomas. You may be considered if your lymphoma has come back or worsened despite prior treatment, and the study checks whether this pill combination can help control the disease.
Miami, FloridaAges 18 years+ - NCT04616560RecruitingPhase 2
New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
Birmingham, AlabamaAges 12–39
Hear when a new Relapsed or Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory peripheral t cell lymphoma?
- Yes. Clin2 currently lists 1,702 recruiting relapsed or refractory peripheral t cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory peripheral t cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory peripheral t cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed Peripheral T-Cell Lymphoma
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.